Adverse Events Module

Adverse Events Module

For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.

Adverse Events Module path is as follows:

Study -> Results Section -> Adverse Events Module -> Event Groups

Study -> Results Section -> Adverse Events Module -> Serious Events

Study -> Results Section -> Adverse Events Module -> Other Events

Adverse Events Module


Ignite Creation Date: 2025-12-25 @ 4:25 AM
Ignite Modification Date: 2025-12-26 @ 3:28 AM
NCT ID: NCT02378220
Description: The adverse events were not tracked and was not an outcome of our study. However, we compared differences in the distribution of CYP 450 metabolic phenotypes, and differences in the severity of drug-drug interactions (DDI) (binary and cumulative), drug-gene interactions (DGI), or drug-drug-gene interactions (DDGI) between this home health trial and another published study population.
Frequency Threshold: 0
Time Frame: We compared primary and exploratory composite outcomes (re-hospitalizations, ED visits and mortality) between the tested group and the untested group at 30 and 60 days post-discharge. The adverse events were not recorded.
Study: NCT02378220
Study Brief: Pharmacogenetic Testing Among Home Health Patients
Event Groups(If Any):

Event Groups

Title Description Deaths # Affected Deaths # At Risk Serious # Affected Serious # At Risk Other # Affected Other # At Risk View
Controls ("Not Tested") Treatment as usual (e.g. review of potential drug-drug interactions via Lexicomp Online) 6 None 0 0 0 0 View
Intervention ("Tested") Patients in the "tested" group will receive pharmacogenetic testing via YouScript® Personalized Prescribing System. The study pharmacist will review drug-drug, drug-gene, and drug-drug-gene interactions using YouScript® to provide drug therapy recommendations to prescribers. Pharmacogenetic testing: Pharmacogenetic testing via YouScript® Personalized Prescribing System 1 None 0 0 0 0 View
Serious Events(If Any):
Other Events(If Any):